
    
      This is a randomized, double-blind, placebo-controlled study to assess the safety,
      tolerability, efficacy, PK, and PD of the chimeric dopamine-somatostatin receptor agonist,
      TBR-760, in adult patients with NFPA over 52 weeks. Approximately 150 patients will be
      enrolled.
    
  